Transplantation for Patients With Chronic Lymphocytic Leukemia
Overview
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.
Full Title of Study: “Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 2010
Detailed Description
To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.
Interventions
- Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
- Procedure: ablative allogeneic hematopoietic cell transplant
Clinical Trial Outcome Measures
Primary Measures
- Efficacy
Secondary Measures
- Feasibility
- Toxicity
- olymerase Chain Reaction (PCR) for minimal residual disease
Participating in This Clinical Trial
Inclusion Criteria
- adequate organ function – normal bone marrow cytogenetics Exclusion Criteria:
- active CNS disease – For autologous patients more than 30% bone marrow involvement
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Stanford University
- Provider of Information About this Clinical Study
- Principal Investigator: Robert Negrin, Professor – Stanford University
- Overall Official(s)
- Robert S Negrin, Principal Investigator, Stanford University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.